Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, Delhi, India.
Department of Pathology, Institute of Liver and Biliary Sciences, Delhi, India.
Nanotheranostics. 2022 Jun 21;6(4):365-375. doi: 10.7150/ntno.70999. eCollection 2022.
Liver diseases are responsible for over 2 million deaths each year and the number is rapidly increasing. There is a strong link between edibles, gut microbiota, liver fat and the liver damage. There are very limited therapeutic options for treatment specifically for Alcoholic liver disease (ALD) and Non-Alcoholic liver disease (NAFLD). Recently, identified Edible Exosomes-like nanoparticles (ELNs) are plant derived membrane bound particles, released by microvesicular bodies for cellular communication and regulate immune responses against many pathogens. Many studies have identified their role as hepatoprotective agent as they carry bioactive material as cargoes which are transferred to recipient cells and affect various biological functions in liver. They are also known to carry specific miRNA, which increases the copy number of beneficial bacteria and the production of lactic acid metabolites in gut and hence restrains from liver injury through portal vein. Few in-vitro studies also have been reported about the anti-inflammatory, anti-oxidant and detoxification properties of ELNs which again protects the liver. The properties such as small size, biocompatibility, stability, low toxicity and non-immunogenicity make ELNs as a better therapeutic option. But, till now, studies on the effect of ELNs as therapeutics are still at its infancy yet promising. Here we discuss about the isolation, characterization, their role in maintaining the gut microbiome and liver homeostasis. Also, we give an outline about the latest advances in ELNs modifications, its biological effects, limitations and we propose the future prospective of ELNs as therapeutics.
肝脏疾病每年导致超过 200 万人死亡,而且这个数字还在迅速增加。食品、肠道微生物群、肝脏脂肪和肝损伤之间存在着很强的联系。目前,针对酒精性肝病 (ALD) 和非酒精性肝病 (NAFLD),治疗方法非常有限。最近,鉴定出的可食用外泌体样纳米颗粒 (ELN) 是植物来源的膜结合颗粒,由微泡体释放,用于细胞间通讯,并调节对许多病原体的免疫反应。许多研究已经确定了它们作为肝保护剂的作用,因为它们携带生物活性物质作为货物,这些货物被转移到受体细胞,并影响肝脏中的各种生物学功能。它们也被认为携带特定的 miRNA,增加有益细菌的拷贝数,并在肠道中产生乳酸代谢物,从而通过门静脉抑制肝损伤。也有一些关于 ELN 的抗炎、抗氧化和解毒特性的体外研究报告,这再次保护了肝脏。ELN 具有体积小、生物相容性、稳定性、低毒性和非免疫原性等特性,使其成为更好的治疗选择。但到目前为止,关于 ELN 作为治疗剂的研究仍处于起步阶段,但前景广阔。在这里,我们讨论了 ELN 的分离、表征及其在维持肠道微生物群和肝脏内稳态中的作用。此外,我们还概述了 ELN 修饰、生物学效应、局限性的最新进展,并提出了 ELN 作为治疗剂的未来前景。